Condition or Therapy:

Leukemia and lymphoma 

Category:

Cancer and Blood Disorders

What is the goal of this study?

PLAT-05 is a first-in-the-nation pediatric phase 1 trial that tests the safety and feasibility of CAR T cells that have been reprogrammed to target CD19 and CD22 proteins simultaneously. CD19 and CD22 are expressed by most leukemia cells. 

Our researchers developed PLAT-05 as an investigational treatment option that will hopefully lead to long-term remission for patients whose cancer expresses CD19 and CD22.

We have several Pediatric Leukemia Adoptive Therapy (PLAT) trials that are also open for enrollment at Seattle Children’s: 

Learn how CART-cell therapy works

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are ages 1 to 26 years old
  • Have relapsed or refractory pre-B acute lymphoblastic leukemia (ALL) or other CD19+ or CD22+ acute leukemia or CD19+ non-Hodgkin lymphoma. It is not open to young people with other leukemias or other childhood cancers.

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

You can read the complete PLAT-05 study protocol on clinicaltrials.gov.

Who can I contact for more information?

Please email or call us at 206-987-2106 to learn more about the study.


Study Location(s):

Seattle Children's Hospital main campus 

Principal Investigator:

Dr. Rebecca Gardner